Viz.ai gets FDA-approved De Novo for heart disease detection using artificial intelligence
The US Food and Drug Administration’s approval of hypertrophic cardiomyopathy for Viz.ai establishes a new category for cardiovascular machine learning-based notification software. why does it matter Viz.ai, a company that…